STOCK TITAN

Atea Pharmaceuticals director sells 41,226 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky exercised 75,000 stock options at $1.24 per share from November 16 through November 18, 2026, receiving common shares. He sold 41,226 shares across those dates: 14,254 at a weighted average $4.2683 on November 16, 8,720 at $4.0316 on November 17, and 18,252 at $3.9502 on November 18. The sales were reported as executed to pay the options’ exercise price and for tax-planning purposes. The options were fully vested and exercisable, and no Rule 10b5-1 plan is reported.

Insider Polsky Bruce
Role Director
Sold 41,226 shs ($168K)
Approx. gross sale proceeds $168K
Approx. exercise cost $93K
Share of Position Sold 20.6%
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F4 18,252 $0.00 $0.00
Exercise Common Stock 18,252 $1.24 $23K
Sale Common Stock F3 18,252 $3.9502 $72K
Exercise Stock Option (Right to Buy) F4 8,720 $0.00 $0.00
Exercise Common Stock 8,720 $1.24 $11K
Sale Common Stock F2 8,720 $4.0316 $35K
Exercise Stock Option (Right to Buy) F4 48,028 $0.00 $0.00
Exercise Common Stock 48,028 $1.24 $60K
Sale Common Stock F1 14,254 $4.2683 $61K
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 158,580 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 75,000 to 0 options (Direct); Common Stock, 124,806 to 158,580 shares (Direct)
Footnotes (4)
  1. F1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. F2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. F3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4. The option is fully vested and exercisable.
Options exercised 75,000 underlying shares November 16–18, 2026; exercise price was $1.24 per share
Exercise price $1.24 per share Options exercised from November 16 through November 18, 2026
Shares sold 41,226 shares Across transactions from November 16 through November 18, 2026
Weighted-average sale price $4.2683 per share 14,254 shares sold November 16, 2026
Weighted-average sale price $4.0316 per share 8,720 shares sold November 17, 2026
Weighted-average sale price $3.9502 per share 18,252 shares sold November 18, 2026
weighted average price financial
"the reported sale price is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Rule 10b5-1 plan regulatory
"no Rule 10b5-1 plan is reported"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AVIR options did director Bruce Polsky exercise, and at what price?

Bruce Polsky exercised 75,000 options at $1.24 per share across three dates. He exercised 48,028 options on November 16, 8,720 on November 17, and 18,252 on November 18, 2026; the options were fully vested and exercisable.

How many AVIR shares did Bruce Polsky sell, and at what prices?

He sold 41,226 shares across three dates: 14,254 at a weighted average price of $4.2683 on November 16, 8,720 at $4.0316 on November 17, and 18,252 at $3.9502 on November 18, 2026. The reported weighted-average prices covered multiple transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Polsky Bruce

(Last)(First)(Middle)
225 FRANKLIN STREET
SUITE 2100

(Street)
BOSTON MASSACHUSETTS 02110

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026M48,028A$1.24172,834D
Common Stock11/16/2026S14,254D$4.2683(1)158,580D
Common Stock11/17/2026M8,720A$1.24167,300D
Common Stock11/17/2026S8,720D$4.0316(2)158,580D
Common Stock11/18/2026M18,252A$1.24176,832D
Common Stock11/18/2026S18,252D$3.9502(3)158,580D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.2411/16/2026M48,028 (4)12/08/2026Common Stock48,028$026,972D
Stock Option (Right to Buy)$1.2411/17/2026M8,720 (4)12/08/2026Common Stock8,720$018,252D
Stock Option (Right to Buy)$1.2411/18/2026M18,252 (4)12/08/2026Common Stock18,252$00D
Explanation of Responses:
1. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
4. The option is fully vested and exercisable.
Remarks:
All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.
/s/ Andrea Corcoran, as Attorney-in-Fact for Bruce Polsky11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading